CMS reassigns Gastric Alimetry code 0868T to APC 5724 at $1,048.77 for 2027
The 2027 OPPS final rule lifts the payment tier for Alimetry's gastric test from 1 January. The change shows how APC placement drives diagnostic economics, though key details are still unconfirmed.
What happened
Alimetry Inc. says the 2027 Hospital Outpatient Prospective Payment System (OPPS) final rule reassigns CPT code 0868T, which covers its Gastric Alimetry test, to Ambulatory Payment Classification (APC) 5724. The national unadjusted payment for that APC is $1,048.77, effective 1 January 2027.
The company's announcement describes the move as a reassignment to a higher payment level. The URL of its release refers to an increase of approximately 144% in Medicare hospital outpatient payment. The records do not include the prior APC, the previous payment rate or the arithmetic behind that figure. All of this comes from the company, so teams should check it against the CMS final rule addenda before using it in models.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Sources this analysis is based on
- CMS moves Alimetry's Gastric Alimetry test to higher Medicare outpatient payment tier for 2027 Alimetry Inc. · Wed 18 Nov 2026
- Getinge recalls CARDIOSAVE balloon pumps in Canada over reversed-polarity capacitors Health Canada · Thu 19 Nov 2026
- ICU Medical recalls Portex endotracheal tubes in Canada over plasticizer variability in resin Health Canada · Thu 19 Nov 2026
- ANSM sets new accreditation procedures for external quality control bodies, replacing 2019 order ANSM · Thu 19 Nov 2026
- Slovenia asks wholesalers to import lidocaine chloride gel amid supply disruption JAZMP · Thu 19 Nov 2026
- AIFA activates web monitoring registry for ZIIHERA in HER2-positive biliary tract cancer AIFA · Thu 19 Nov 2026
Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.
Safety judgment belongs apart from the product line, and CBER just said so
FDA's new CBER Safety Council sits outside the product offices. PV leaders should test whether their own safety decisions have the same structural distance from commercial pressure.
Definitions decide pathways: UK gene therapy rewrite means check your category now
The UK will widen its gene therapy definition to catch synthetic and genome-editing products. Regulatory teams should test their pipelines against the new boundary before the legislation arrives.
EMA's CMV immunoglobulin PSUSA ends in maintenance: what a quiet outcome tells PV teams
EMA has closed its periodic safety review of cytomegalovirus immunoglobulin with the marketing authorisations maintained. What the outcome does and does not tell MAHs is worth spelling out.